Shield Therapeutics

16 Dec 2022 - Circular

08 Sep 2022 -  Business Update and Interim Report for the six months ended 30 June 2022

27 Jul 2022  - Results of Annual General Meeting

27 Jul 2022 -  Results of General Meeting

08 Jul 2022 -  Notice of General Meeting - Letter to Shareholders

08 Jul 2022 - Notice of General Meeting

30 Jun 2022 - Notice of Annual General Meeting

30 Jun 2022 - Notice of Annual General Meeting: Letter to shareholders

06 Dec 2024 - AOP Irrevocable Undertaking

06 Dec 2024 - Peel Hunt Consent Letter

06 Dec 2024 - Shareholder Circular

06 Dec 2024 - Director's Irrevocable Undertaking - Hans Peter Hasler

06 Dec 2024 - Directors's Irrevocable Undertakings - P Llewellyn-Davies

06 Dec 2024 - Director's Irrevocable Undertaking - Fabiana Lacerca-Allen

06 Dec 2024 - Director's Irrevocable Undertaking - Dr Christian Schweiger

06 Dec 2024 - Director's Irrevocable Undertaking - Anders Lundstrom

06 Dec 2024 - AOP Relationship Agreement

06 Dec 2024 - AOP Subscription Agreement

06 Dec 2024 - AOP Accounts for the year ended 2023

06 Dec 2024 - Articles of Association of AOP Health International Management AG

06 Dec 2024 - AOP Accounts for the year ended 2022

09 Sep 2024 - H1 2024 Interim Financials

20 Jun 2024 - Results of Annual General Meeting

10 May 2024 - Notice of General Annual Meeting 

10 May 2024 - Letter to Shareholders

10 May 2024 - Audited results for the year ended 31 December 2023

30 Apr 2024 - Business Update for Q1 2024 and Confirmation of Key Financials for FY 2023

2024 Annual Report & Accounts

2023 Annual Report & Accounts

2022 Annual Report & Accounts

2021 Annual Report & Accounts

2020 Annual Report & Accounts

22 May 2025 - Results of AGM 

25 Apr 2025 - Notice of General Annual Meeting

25 Apr 2025 - Letter to Shareholders

24 Feb  2025 - Anders Lundstrom CEO: 2024 Year in Review & Strategic Outlook for 2025

28 Sep 2023 -  STX Interim Results

28 Sep 2023 - Interim results update and business update

29 Jun 2023 -  Results of Annual General Meeting

19 May 2023 Notice of Annual General Meeting

19 May 2023  - Letter to Shareholders

27 Apr 2023 - Final Results and Q1 Update

27 Apr 2023 - Business Update and Unaudited Results

05 Jan 2023 - Results of General Meeting

17 Aug 2021 -  Interim Report for the six months ended 30 June 2021

17 Jun 2021 -  AGM Results

13 May 2021 -  Notice of Annual General Meeting: Letter to Shareholders

13 May 2021 - Annual Report and Accounts for the year ended 31 December 2020

29 Apr 2021 - Preliminary results for the Year Ended 31 December 2020

18 Mar 2021 -  Result of General Meeting & Open Offer

01 Mar 2021 - Shareholder Placing: Subscription Circular - Notice of GM

20 Jun 2021 - Notice of Annual General Meeting

Financials

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Careers

Partnerships

Overview

Contact and Locations

Leadership

Announcements

Webinars

Media

Portfolio

Publications

ID/IDA Facts and Figures

Approved Medicine

Corporate Governance

Analysts & Advisors

AIM Rule 26

Stock Information

Investor Overview

Noto Sans

“Achieving positive cash flow represents an important inflection point for the Company and positions us to fund ongoing growth internally. In 2025, the execution of our commercial strategy drove record performance for ACCRUFeR®, with meaningful gains across prescription demand, pricing, and revenue. The strong finish to the year, together with an improved balance sheet, leaves us well positioned to advance our objectives in 2026 while continuing to strengthen the long-term financial profile of the business.”

Santosh Shanbhag, Chief Financial Officer

2025 has been another strong year of growth for Shield, highlighted by a significant increase in sales, net selling price, and the number of ACCRUFeR® prescriptions in the U.S. We are especially proud that ACCRUFeR® has now been approved by the FDA for adolescents aged 10 and over, expanding the patient population who can benefit from this well-tolerated and effective therapy for ID/IDA.

Demand for ACCRUFeR® continues to rise both in the U.S. and across all our territories, with net sales, total prescriptions, and net selling price all showing positive trends. Shield remains focused on increasing awareness of ACCRUFeR® among healthcare professionals in the U.S., expanding our geographic reach through international partners, and significantly enhancing global access to this important therapeutic option whilst actively seeking strategic in-licensing and out-licensing opportunities to strengthen our portfolio.

Importantly, Shield has achieved cash flow positivity, reflecting the strength of our financial foundation. Exiting 2025 with a stronger balance sheet, effective cost-saving measures, and a thriving U.S. market presence, we are well-positioned to execute our strategy with confidence and continue delivering value to patients, healthcare providers, and shareholders.